Streetbeat News

EQRX

EQRx Inc

https://www.eqrx.com

CEO

Melanie I. Nallicheri

Employees

240

Industry

Research and Development in Biotechnology

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.

Open

2.39

Mkt cap

1.1B

Volume

12M

High

2.42

P/E Ratio

-4.25

52-wk high

4.75

Low

2.32

Div yield

N/A

52-wk low

1.58

Revolution Medicines, Inc. (NASDAQ:RVMD) and EQRx, Inc. (NASDAQ:EQRX) stockholders have approved Revolution Medicines' proposed acquisition of EQRx. The transaction is expected to close in November 2023. Upon completion, each share of EQRx will be converted into 0.1112 shares of Revolution Medicines. Revolution Medicines expects to issue approximately 55 million shares of its common stock in connection with the merger.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 4:33 pm

EQRx has provided a written notice to G1 Therapeutics, terminating the exclusive license agreement dated July 22, 2020. The termination will be effective as per the terms of the agreement.

Portfolio Pulse from Charles Gross

August 04, 2023 | 2:44 pm

The article lists the stocks that gained and lost the most in Tuesday's mid-day session. Among the gainers, Adamis Pharmaceuticals Corporation (ADMP) shares gained 188.8% to $4.13, and Yellow Corporation (YELL) surged 79% to $3.15 on news of bankruptcy. Among the losers, Polished.com Inc. (POL) shares dipped 68.7% to $0.1974, and TG Therapeutics, Inc. (TGTX) fell 48.4% to $10.70.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 10:08 am

EQRx is set to be acquired by Revolution Medicines in an all-stock transaction, leading to a rise in EQRx's share prices.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 9:58 am

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Adamis Pharmaceuticals, ABVC BioPharma, Ampio Pharmaceuticals, Rhythm Pharmaceuticals, EQRx, and Revolution Medicines saw their shares increase, while TG Therapeutics, BioXcel Therapeutics, Adial Pharmaceuticals, OKYO Pharma, eFFECTOR Therapeutics, and Tarsus Pharmaceuticals experienced a decrease in their stock prices.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 9:54 am

Revolution Medicines Inc (RVMD) has agreed to acquire EQRx Inc (EQRX) in an all-stock transaction that will add over $1 billion to RVMD's balance sheet. The deal is expected to close in November 2023. Post-merger, RVMD will focus on its three priority RAS-focused assets and will not advance EQRX's R&D portfolio. EQRX will wind down these programs and return the associated IP to its partners.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 9:45 am

Despite a general downturn in the US stock market, several companies saw significant gains. American Superconductor Corporation (AMSC) jumped 49% amid claims of a new superconductor. Nikola Corporation (NKLA) gained 21% after being awarded an additional $16.3 million for hydrogen refueling stations. Rhythm Pharmaceuticals (RYTM), Arista Networks (ANET), and AudioCodes (AUDC) all saw gains following strong quarterly sales or better-than-expected results. EQRx (EQRX) gained 14.3% following an announcement of its acquisition by Revolution Medicines. Other companies such as Emergent BioSolutions (EBS), Proterra (PTRA), Great Lakes Dredge & Dock Corporation (GLDD), Mativ Holdings (MATV), Douglas Dynamics (PLOW), TETRA Technologies (TTI), Varonis Systems (VRNS), HUTCHMED (HCM), SunCoke Energy (SXC), Rigetti Computing (RGTI), Oshkosh Corporation (OSK), Caterpillar (CAT), and Global Payments (GPN) also recorded gains.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 9:30 am

During Tuesday's pre-market session, several healthcare stocks experienced significant movements. ABVC BioPharma, Ampio Pharmaceuticals, EQRx, Cadrenal Therapeutics, Creative Medical Tech, and Vapotherm saw their shares rise, with ABVC BioPharma leading the gainers with a 92% increase. On the other hand, TG Therapeutics, OKYO Pharma, Mallinckrodt, Revolution Medicines, Aeglea BioTherapeutics, and Trevi Therapeutics saw their shares fall, with TG Therapeutics experiencing the largest drop of 38.2%.

Portfolio Pulse from Benzinga Insights

August 01, 2023 | 2:25 pm

Revolution Medicines, Inc. (RVMD) has announced plans to acquire EQRx, Inc. (EQRX) in an all-stock transaction. The deal is expected to add more than $1 billion in net cash to Revolution Medicines' balance sheet. The number of shares to be issued to EQRx security holders will be determined close to the closing of the stockholder votes on the transaction. The transaction has been approved by the directors of both companies.

Portfolio Pulse from Charles Gross

August 01, 2023 | 11:33 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.